Clinical trial · Interventional
Comparison of Record in VERITON Camera to the Anger Camera Procedure in Patients Treated by 131-iodine
Comparison of a 3D Recording in a VERITON-CT™ Camera to the Anger Camera Procedure in Patients Treated by Iodine 131 for a Thyroid Cancer
NCT05713123CI-TRIAL-00078070VERICATHunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to show that the SPECT/CT whole body recording procedure lasting less than or equal to 30 minutes in a VERITON-CT™ camera, can be substituted for the classic procedure, giving at least equivalent information in searches for primary or metastatic neoplastic lesions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Device | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A SPECT-CT whole body is added in VERITON-CT camera | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Person suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq)
- description
- The study will be offered to patients suffering from thyroid cancer and treated by iodine 131 (1100 MBq or 3700 MBq). When they come in nuclear medicine to have the iodine scan in Anger's camera, if they signed the consent, they will the SPECT/CT whole body in VERITON-CT camera
- interventionNames
- Other: A SPECT-CT whole body is added in VERITON-CT camera
Primary outcomes (1)
- measure
- Compare post-therapy imaging performed with the two procedures
- timeFrame
- 18 months
- description
- Type of lesions * Lesions * The nature of the lesion(s): thyroid residue and/or lymph node lesion and/or metastases (distant lesions). * Number of lesions in conventional camera and in VERITON-CT™ camera.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients over the age of 18, who have understood and signed the informed consent form. 2. Person suffering from thyroid cancer and for whom the multidisciplinary meeting has validated a treatment by iodine 131 (1100 MBq or 3700 MBq). 3. Person with no contraindication to carrying out the examination. 4. Person affiliated to a social security scheme. Exclusion Criteria: 1. Person with a known allergy to one of the components of the radiopharmaceutical (Iodine 131 capsule). 2. Pregnant woman or woman of childbearing age and without suitable contraceptive means, or breastfeeding mother. 3. Person whose medical condition is unstable and/or unable to remain still in the supine position during recordings. 4. Person deprived of liberty by a judicial or administrative decision. 5. Person of full age subject to a measure of legal protection (guardianship, curators, safeguard of justice). 6. Adult person unable to express his consent and who is not the subject of a legal protection measure.
References
Publications (0)
Data not yet available
No reference posted for this study.